According to a new study, topical calcineurin inhibitors such as pimecrolimus and tacrolimus did not increase cancer risk in atopic dermatitis (AD) patients.
Many pediatric HS patients do not meet diagnostic criteria, new study shows
Over one third of pediatric patients with hidradenitis suppurativa (HS) did not meet all three major diagnostic criteria at the time of diagnosis, according to a new study.
Study shows HS patients who feel stigmatized report worse QOL, mental health outcomes
Patients with hidradenitis suppurativa (HS) who report feelings of stigmatization from their condition had worse quality of life (QOL) and higher levels of depression, according to a new study.
Study shows AD and bacterial skin infections higher in Indigenous youth
A recent study has shown that atopic dermatitis (AD) and bacterial skin infection rates are higher in Indigenous youth compared to their non-Indigenous peers in high-income countries.
Prolonged corticosteroid exposure linked to adverse effects in AD patients, study shows
A recent study found that adult and pediatric atopic dermatitis (AD) patients experienced more adverse effects after prolonged use of corticosteroids.
New study shows tralokinumab use for AD not related to Covid-19 severity
Tralokinumab treatment in patients with moderate-to-severe atopic dermatitis (AD) does not increase Covid-19 severity or interfere with Covid-19 vaccinations, according to a new study.
New study shows digital intervention may increase treatment adherence in AD patients
A digitally delivered intervention showed significant improvements in treatment adherence and other clinical outcomes in atopic dermatitis (AD) patients, according to a new study.
Black HS patients experience worse outcomes than White patients
According to a new study, Black hidradenitis suppurativa (HS) patients are more likely to experience greater disease severity, hospitalizations, emergency department visits and surgeries than White patients.
Real world study shows apremilast safe to treat PsO, PsA patients
A real-world study of psoriasis (PsO) and psoriatic arthritis (PsA) patients with apremilast reported no new adverse events or safety signals with results comparable to previous clinical trials.
Suppressing key metabolic enzyme may stop melanoma growth, new study shows
A new study has discovered that by inhibiting the key metabolic enzyme Glutaryl-CoA Dehydrogenase (GCDH), melanoma cells can be selectively killed to halt tumour growth.
HealthMinute.TV 